Stock Analiz

Journey Medical Corp DERM

Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026

$4.33Market cap $122M
Open the interactive analysis →

Journey Medical Corp (DERM) is a healthcare company listed in the US with a market value of about $122M. In the twelve months to September 30, 2026 it had revenue of $70M and net income of -$5M, a net margin of -7.3%.

Its overall Stock Analiz score is 0.2 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 7% a year, a 5-year average ROIC of -30%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 36% below the current price.

About Journey Medical

Journey Medical is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. Revenue went from $45M in 2020 to $62M in 2025, growth of about 6.8% a year. It was profitable in 1 of the last 6 years in our data. Its share count rose by 40% over three years (dilution for shareholders). It spends 1% of revenue on research and development.

Score: 0.2 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health0/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E17.6
P/FCF—
P/S1.8
P/B3.8
EV/EBITDA59.2
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price−36%

Growth and quality

Revenue growth (1 yr)10.2%
Revenue growth (5 yrs, per year)6.8%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-31.9%
ROIC (5-yr avg.)-30.5%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 6 years

Fiscal yearTTM202520242023202220212020
Revenue$70M$62M$56M$79M$74M$63M$45M
Net income-$5M-$11M-$15M-$4M-$30M-$44M$5M
Free cash flow——-$24M$240000-$34M——
EPS (diluted)$-0.18$-0.47$-0.72$-0.21$-1.69$-4.32$0.49
Net margin-7.3%-18.5%-26.1%-4.9%-40.2%-69.7%11.9%
ROIC—-11.3%-23.9%-4.7%-48.4%-64.1%55.4%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 3 analysts is $13.33, 208% above the current price; targets range from $13.00 to $14.00; the consensus rating is “Strong buy”; expected EPS is $-0.07 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Journey Medical stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 36% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Journey Medical pay a dividend?

Not currently.

Is Journey Medical a good stock to buy?

We do not give buy or sell advice. Journey Medical scores 0.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.